In the Claims:

Please cancel claims 14 to 28 without prejudice and add new claims 29 to 45:

Claims 1 to 13 (previously canceled).

Claims 14 to 28 (canceled).

29(new). Injectable oligomer-polymer composition consisting of a combination of at least one bioactive substance and a mixture of at least two biodegradable excipients, wherein the at least two biodegradable excipients are oligomeric esters of hydroxycarboxylic acids and/or polymeric esters of hydroxycarboxylic acids.

30(new). Injectable oligomer-polymer composition as defined in claim 29, wherein the at least two biodegradable excipients are polymerization products of identical or different hydroxycarboxylic acids.

31(new). Injectable oligomer-polymer composition as defined in claim 30, wherein said hydroxycarboxylic acids are lactic acid and glycolic acid.

32(new). Injectable oligomer-polymer composition as defined in claim 29, wherein at least one of said biodegradable excipients is a liquid low molecular weight oligomer and at least one other of said biodegradable excipients is a solid

high molecular weight polymer.

33(new). Injectable oligomer-polymer composition as defined in claim 32, wherein the liquid low molecular weight oligomer is a compound of formula I, a compound of formula II or a compound of formula III:



I



II



III

wherein R for variables m, n, o, p, q and r is identical or different and represents $-CH_2-$, $-CH(CH_3)-$, $-(CH_2)_5-$, $-CH_2-CH_2-O-CH_2-$, $-CH_2-CH_2-O-CH_2-CH_2-O-CH_2-$, or homologues thereof, in each case with up to 5 further C atoms;

wherein R_1 represents $-CH_2-COOY$, $-CH(CH_3)-COOY$, $-CH_2-CH_2-COOY$, $-CH_2-CH_2-CH_2-COOY$, $-CH_2-CH_2-CH_2-CH_2-COOY$, $-CH_2-CH_2-CH_2-CH_2-CH_2-COOY$, $-CH_2-CH(CH_3)-Y$, $-(cyclo-C_6H_{11})$ or $-CH_2-C_6H_5-$;

wherein R_2 represents $-CH_2-CH(CH_3)-$, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-CH_2-$, $-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-$, $-CH_2-CH(-Y)-CH_2-$, cyclohexane-1,2-diyl, cyclohexane-1,3-diyl or cyclohexane-1,4-diyl;

wherein R_3 represents $(-CH_2)_2CH-$, $(-CH_2)_3C-CH_3$ or $(-CH_2)_3C-CH_2-CH_3$, where Y is -H, $-CH_3$, $-C_2H_5$, $-C_3H_7$ or $-C_4H_9$, and m, n, o, p, q and r denote, independently of one another, an integer

from 2 to 18.

34. Oligomer-polymer composition as defined in claim 33, wherein R denotes $-CH(CH_3)-$, R_1 denotes $-CH(CH_3)-COOY$ with $Y = -C_2H_5$, and m, n, o, p, q or r denotes, independently of each other, an integer from 2 to 4.

36. Oligomer-polymer composition as defined in claim 32, wherein the liquid low molecular weight oligomer is at least one poly(hydroxyester) and/or a copolymer thereof.

37. Oligomer-polymer composition as defined in claim 36, wherein said at least one poly(hydroxyester) is a poly(L-lactide), a poly(D,L-lactide), a poly(glycolide), a poly(caprolactone), a poly(dioxanone), a poly(hydroxybutyric acid), a poly-(hydroxyvaleric acid), a poly(glycosalicylate) and/or a product of ring-opening polymerization of a lactone in the presence of a biocompatible starter molecule.

38. Oligomer-polymer composition as defined in claim 37, wherein said biocompatible starter molecule is an alkyl L-lactide, cholesterol, propane-1,2-diol, triethylene glycol, glycerol or pentaerythritol.

39. Oligomer-polymer composition as defined in claim 32, wherein solid high molecular weight polymer and said liquid low molecular weight polymer are present in a ratio of 1:100 to 1:1.

40. Oligomer-polymer composition as defined in claim 39, wherein said ratio is from 1:10 to 1:2.

41. Oligomer-polymer composition as defined in claim 29, wherein said at least one bioactive substance is selected from the group consisting of hormones, immunomodulators, immunosuppressants, antibiotics, cytostatics, diuretics, gastrointestinal agents, cardiovascular agents and neuropharmaceuticals.

42. Oligomer-polymer composition as defined in claim 41, wherein said at least one bioactive substance is present in said mixture of said at least two biodegradable excipients in dissolved or suspended form.

43. Oligomer-polymer composition as defined in claim 29, in the form of an injectable composition, which, after injection, forms a coagulum under the influence of a body fluid.

44. An injectable implant obtained by injecting an oligomer-polymer composition, said oligomer-polymer composition being defined as in claim 29.

45. A method of preparing an implant in a mammal, said method comprising the step of injecting said oligomer-polymer composition as defined in claim 29 into said mammal.